What is Otonomy?
Otonomy is a biopharmaceutical firm dedicated to pioneering novel therapeutics for neurotology. The company's core innovation lies in its drug delivery technology, designed to achieve sustained drug exposure through a single local administration within the ear. This patented approach targets significant unmet medical needs in hearing loss and tinnitus, positioning Otonomy at the forefront of specialized ear therapeutics.
How much funding has Otonomy raised?
Otonomy has raised a total of $448.4M across 7 funding rounds:
Series A
$10M
Series B
$38.5M
Series C
$45.9M
Series D
$49M
Stock Offering
$104M
Stock Offering
$86M
Stock Offering
$115M
Series A (2010): $10M with participation from Avalon Ventures
Series B (2010): $38.5M led by Domain Associates, TPG Biotech, RiverVest Venture Partners, Novo Ventures, and Avalon Ventures
Series C (2013): $45.9M supported by Novo Ventures, Avalon Ventures, APERTURE Venture Partners, Domain Associates, OrbiMed, TPG Biotech, Osage University Partners, and RiverVest Venture Partners
Series D (2014): $49M featuring Clough Capital Partners, APERTURE Venture Partners, Jennison Associates, Federated Kaufmann Funds, Perceptive Advisors, Domain Associates, OrbiMed, TPG Biotech, Ally Bridge Group, Osage University Partners, RiverVest Venture Partners, Novo Ventures, and Avalon Ventures
Stock Issuance/Offering (2014): $104M backed by Undisclosed
Stock Issuance/Offering (2015): $86M with participation from Undisclosed
Stock Issuance/Offering (2016): $115M led by Undisclosed
Key Investors in Otonomy
Novo Ventures
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, established in 1999 and headquartered in Hellerup, Denmark, focusing on life sciences investments.
Domain Associates
DomainVC is an investment advisory firm established in 1985, specializing in biotech investments with a strong track record of funding biopharmaceutical, device, and diagnostic companies, leading to numerous IPOs and M&A events.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services, with deep expertise in life sciences and healthcare business development.
What's next for Otonomy?
With substantial backing, Otonomy is poised to advance its pipeline of treatments for hearing loss and tinnitus. The company's strategic investments indicate a strong market belief in its innovative drug delivery platform. Future developments will likely focus on clinical trial progression, regulatory approvals, and eventual commercialization, aiming to address critical needs within the neurotology field and solidify its market position.
See full Otonomy company page
